Navigation Links
Starfish Ventures Closes Australia's Largest Venture Capital Fund With $185 Million Tech Fund
Date:11/12/2008

MELBOURNE, Australia, Nov. 12 /PRNewswire/ -- Melbourne-based Starfish Ventures announced today the successful closure of its Starfish Technology Fund II at $185 million, the largest venture capital fundraising in Australia. The fund will invest in ICT, Life Sciences and Cleantech companies.

The success of this fundraising is an endorsement of Starfish Ventures and an endorsement of Australia's ability to foster the development of innovative companies that, with the right support, can be transformed into successful global businesses. The current fund brings Starfish's funds under management to more than $385 million.

Investments in Starfish Technology Fund II include Ausra, Aruspex, Monitoring Division and Pro-Active Medical, and all investors in the current fund were also investors in the prior fund -- evidence, according to Starfish Investment Principal, Michael Panaccio, of the company's strong record of success in backing innovative companies with the potential to become global leaders.

Starfish Ventures has announced the closure of its fundraising for Starfish Technology Fund II at $185 million -- the largest venture capital fundraising in Australia -- bringing total funds under management to more than $385 million. Starfish Technology Fund II will focus on Information and Communications Technology, Life Sciences and Cleantech.

Seven investments have been made under Starfish Technology Fund II to date:
Cleantech: Myriax and Ausra

ICT: 5th Finger, Aruspex , Monitoring Division, and Ofidium

Life Sciences: Pro-Active Medical

"Starfish is pleased to raise $185 million for Starfish Technology Fund II in what has turned out to be a difficult fundraising environment," said Dr. Panaccio, Starfish Ventures Investment Principal, "We're delighted that the Starfish Technology Fund II investors were also investors in our previous fund."

"Starfish Ventures will continue to build on our past successes, such as Distra, Engana and ImpediMed, all of which have successfully created new global markets. We are committed to continue partnering with great management teams to transform innovative Australian technology into great global businesses."

STARFISH TECHNOLOGY FUND II INVESTMENTS

Cleantech

-- Myriax: Produces high quality aquaculture technology and environmental

data analysis and visualization software.

-- Ausra: A solar thermal energy company providing solar power, steam and

energy systems for industrial processes and utility-scale electricity

generation.

Information and Communications Technology

-- 5th Finger: Develops mobile marketing technology for the creation,

management and execution of marketing campaigns on mobile devices.

-- Aruspex: Delivers strategic workforce planning solutions that help

organisations design and attain their future workforce.

-- Monitoring Division: Develops technology for identifying and monitoring

multiple network impairments in optical networks.

-- Ofidium: Develops 100Gps optical transceiver modules to increase the

speed of transmissions to optical networks.

Life Sciences

-- Pro-Active Medical: Develops a medical device for the monitoring of

lower back movement and a feedback device for poor posture.

Media contacts:

Asia/USA Susan Fitzpatrick +61 (0) 400246010

Office +1 650 7985238/+61 (0) 290061614

Tania@datelinemedia.com

Australia: Tania Ewing 0408378422

Office: 02 90061614

Susan@datelinemedia.com


'/>"/>
SOURCE Starfish Ventures
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Hank Plain Joins Morgenthaler Ventures as Partner
2. Dan Broderick Joins Prolog Ventures as Partner
3. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
4. Vivo Ventures Expands Team with the Addition of James Huang as an Executive in Residence
5. Khosla Ventures and BIOeCON Form KiOR Inc.
6. Jerusalem Global Ventures Announces $200 Million Growth Equity Fund
7. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
8. Clarus Ventures Closes $660 Million Fund
9. The Bill & Melinda Gates Foundation, BIO, and Bio Ventures for Global Health Invite Proteome Systems CEO to Speak on TB Diagnostics Solutions At Partnering for Global Health Forum, Washington D.C.
10. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
11. SPO Medical Retains American Capital Ventures for Investor Relations Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , Feb. 17, 2017  If only one ... had a mutation-conferring resistance to chemotherapy, thousands of ... research has focused on finding these mutations in ... from circulating tumor DNA in blood — to ... therapeutics. Unfortunately, however, detecting these genetic ...
(Date:2/16/2017)... 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company ... better treatment for triple negative breast cancer (TNBC), announced today ... program. The YEi Start in ... help entrepreneurs grow their business in France ... companies selected to complete an intensive one week immersion in ...
(Date:2/16/2017)... LOS ANGELES , Feb. 16, 2017 /PRNewswire/ ... CAPR ), a clinical-stage biotechnology company developing first-in-class ... today announced that it has elected to terminate ... to natriuretic peptide receptor agonists, including Cenderitide. ... a strategic move as we prioritize our efforts ...
(Date:2/16/2017)... HACKENSACK, N.J. , Feb. 16, 2017  Champions ... engaged in the development and sale of advanced technology ... of oncology drugs, today announced the addition of new ... These new models will expand Champions, product ... cancer, head and neck cancer, AML, and non-small cell ...
Breaking Biology Technology:
(Date:2/8/2017)... Feb. 7, 2017 Report Highlights ... 2021 from $8.3 billion in 2016 at a compound ... 2021. Report Includes - An overview of the ... trends, with data from 2015 and 2016, and projections ... Segmentation of the market on the basis of product ...
(Date:2/3/2017)... , Feb. 3, 2017  Texas Biomedical Research Institute announced ... Larry Schlesinger as the Institute,s new President and ... effective May 31, 2017. He is currently the Chair of ... the Center for Microbial Interface Biology at Ohio State University. ... the new President and CEO of Texas Biomed," said Dr. ...
(Date:2/1/2017)... IDTechEx Research, a leading provider of independent ... availability of a new report, Sensors for Robotics: Technologies, Markets ... ... ... IDTechEx Report "Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027: Machine ...
Breaking Biology News(10 mins):